New hope for Tough-to-Treat ovarian cancer?
NCT ID NCT02195973
Summary
This early-stage study aimed to find out if adding a new drug called LDE225 to standard chemotherapy (paclitaxel) was safe for women with recurrent ovarian cancer that had stopped responding to platinum-based drugs. The main goal was to check for side effects and determine the best dose of the new combination. It involved 15 participants to gather initial safety data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.